Nivolumab Demonstrates Durable Long-term Survival in Patients with Advanced Cancers

Source: Specialty Pharmacy Times, September 2019

Treatment with nivolumab demonstrated durable survival in previously-treated patients with advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC), according to a new study published in JAMA Oncology.

The study, which included 270 patients, analyzed 5-year survival among those with all 3 cancer types in a phase 1 clinical trial of nivolumab. In the trial, patients received different doses of nivolumab (between 0.1 to 10.0 mg/kg) intravenously in an outpatient clinic every 2 weeks in 8-week cycles for up to 2 years.

Patients in the study were previously treated, with 40.4% having undergone 3 or more prior systemic therapies.